Week Ending January 18, 2022

“Hep ElimiNATION” to Assess and Guide U.S. Efforts to End Hepatitis
“In January 2021, the Department of Health and Human Services (HHS) released the Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination 2021–2025, which spelled out five main goals for the next five years. So did the United States make any progress last year? How can we gauge whether we’re on track to end viral hepatitis? A new partnership between researchers and advocates titled Hep ElimiNATION aims to assess exactly that as well as offer guidance.”

Starting Hepatitis C Treatment at Time of Diagnosis Leads to High Cure Rate
“People with hepatitis C who start direct-acting antiviral treatment when and where they are diagnosed had a high likelihood of achieving a cure, according to study results presented at the 2021 AASLD Liver Meeting. By eliminating the need to navigate the medical system, this model could be a good option for marginalized populations, including people experiencing homelessness and people who inject drugs.”

Animation Aims to Educate on Hepatitis C
“Test!Treat!Cure! features infectious disease physician Dr. MarkAlain Déry and community health expert Dr. Eric Griggs in a 2Tone musical animation. The video uses the upbeat sounds of ska to educate viewers on reducing risks of liver cancer by testing for hepatitis C.”

Racial, ethnic disparities in patients with HCC reveal need to reduce barriers to care
“Among patients newly diagnosed with hepatocellular carcinoma, there are significant racial and ethnic differences in barriers to care, according to survey results published in Clinical Gastroenterology and Hepatology.”

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
“Despite widespread availability of direct-acting antivirals including generic formulations, limited progress has been made in the global adoption of hepatitis C virus (HCV) treatment. Barriers to treatment scale-up include availability and access to diagnostic and monitoring tests, health-care infrastructure, and requirement for frequent visits during treatment.”

Long-Term Prescription Opioid Use Linked to Higher Risk of Hepatitis C
“Prescription opioid use is associated with a significant risk of hepatitis C virus (HCV) seroconversion, according to new research. A team, led by James Wilton, MPH, British Columbia Centre for Disease Control, assessed the link between medically dispensed long-term prescription opioid therapy for noncancer pain and HCV seroconversion among individuals who were initially injection drug use-naïve.”

Can Non-Invasive Medical Devices Help Halt Liver Disease?
“A silent liver disease epidemic is sweeping the country and the world through a rise in chronic liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and its more severe form non-alcoholic steatohepatitis (NASH). NASH can lead to advanced fibrosis and liver cancer, liver transplantation, and increased risk of cardiovascular events and all-cause mortality, while NAFLD is one of the most common causes of liver disease in the United States. Experts state that about 24% of U.S. adults have NAFLD and about 1.5% to 6.5% of U.S. adults have NASH.”

Integrating Predictive Models Into Care: Facilitating Informed Decision-Making and Communicating Equity Issues
“As predictive models proliferate, providers and decision makers require accessible information to guide their use. Preventing and combating bias must also be priorities in model development and in communication with providers and decision makers.”